Richtig G, Wolf M, Schulter G, et al. Body-Mass-Index as a predictive marker for response in patients with metastatic melanoma treated with ipilimumab. SMR 2017, P01-15.
Update KEYNOTE-716: aanhoudend voordeel pembrolizumab bij melanoom
mrt 2024 | Dermato-oncologie